Risk factor
Very high price volatility
Profitability factor
Strong growth
About
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug,...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of MLTX is 14 and suggests 0% downside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Buy
Sell